retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Upcoming wave of hormone-based therapies set to change field of diabetes, care Retatrutide Triple Agonist Research Peptide

other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

In this GLP1 capsule, every natural, premium ingredient works together to support optimal overall health

Here's what clinicians should know.

The new class of weight-loss medications are hailed as game-changing wonder drugs, but just how safe and effective are they

This comprehensive review explores the mechanisms, clinical implications, and mitigation strategies, including exercise, protein intake, and adjunct therapies.